Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
NIH study supports use of short-term HIV treatment interruption in clinical trials

A short-term pause in HIV treatment during a carefully monitored clinical trial does not lead to lasting expansion of the HIV reservoir nor cause irreversible damage to the immune system, new findings suggest.

Published
11 January 2018
From
National Institutes of Health
Teva Announces Exclusive Launch of a Generic Version of Reyataz® in the United States

Reyataz® had annual sales of approximately $402 million in the U.S., according to IMS data as of October 2017.

Published
10 January 2018
From
Teva press release
New long-acting, less-toxic HIV drug suppresses virus in humanized mice

A team of Yale researchers tested a new chemical compound that suppresses HIV, protects immune cells, and remains effective for weeks with a single dose. In animal experiments, the compound proved to be a promising new candidate to enhance current HIV treatment regimens — without increasing toxic side effects, the researchers said.

Published
08 January 2018
From
Yale News
FDA Accepts New Drug Applications for Merck’s Doravirine, the Company’s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection

The NDAs include data for doravirine (DOR) as a once-daily tablet for use in combination with other antiretroviral agents, and for use of doravirine with lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) in a once-daily fixed-dose combination single tablet as a complete regimen (DOR/3TC/TDF).

Published
08 January 2018
From
Merck press release
Immediate HIV Treatment Has Little Impact on Risk of Future Drug Resistance

Starting antiretroviral therapy (ART) immediately rather waiting until a person's CD4 count falls below 500 cells/µL has almost no impact on the person's risk of developing antiretroviral resistance over the next seven years, according to a study published online in the journal AIDS. In this 51,000-person analysis, the impact of immediate ART on acquired drug resistance disappeared almost completely among people starting treatment in 2005 or later.

Published
07 January 2018
From
The Body Pro
Suboptimal ART adherence associated with greater inflammation in patients with HIV

Recently published findings indicate that suboptimal adherence to ART is associated with activation of coagulation and enhanced residual inflammation among patients with HIV, even if patients have already achieved virologic suppression.

Published
07 January 2018
From
Healio
Selective suppression of inflammation could deplete HIV and control HIV activation

A class of anti-inflammatory drugs already FDA-approved for rheumatoid arthritis could "purge" the reservoir of infected immune cells in people infected by HIV, according to new research.

Published
02 January 2018
From
Emory University
Preliminary study hints that genetically modified T cells might fight HIV

The same kind of DNA tinkering that produced the first FDA-approved gene therapy for cancer has shown hints of suppressing and even eradicating HIV infection in lab animals, scientists have reported. Although the study was small — it tested the genetically engineered “CAR” cells on only two monkeys as well as on cells growing in lab dishes — it suggests that after 30 years of fruitless efforts to come up with an AIDS vaccine there might be a wholly new way to get the immune system to fight HIV infection.

Published
02 January 2018
From
STAT
HIV Drugs in the Pipeline: Expected Approvals for 2018

Three specialty HIV medications—three oral medications and one IV formulation—are expected to receive FDA approval in 2018. All of them are combination products geared toward improving adherence.

Published
31 December 2017
From
Infectious Disease Special Edition
Study Finds Sustiva Not Strongly Linked to Suicidal Thoughts

But that is not necessarily the case for those with preexisting mental health problems.

Published
31 December 2017
From
Poz
← First12345...177Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.